The pants don't lie. But the pricing might.

It's genuinely free — there's no cost, no trial and no card required. We just ask for an email so we can send it to you (and let you know when it's updated). If you'd rather use the framework and ignore every link on the site, that's a completely reasonable thing to do — the framework is the valuable part.

Two reasons, and we'd rather say both. First, cheapest headline price is not cheapest annual cost once you account for dose tiers, consult fees and promo resets — that's the entire point of our pricing breakdown. Second, our ranking weighs clinical oversight, pharmacy transparency, support and terms alongside price — so the lowest sticker price doesn't automatically finish first. Use our criteria to judge for yourself, including on providers we don't list.

No. We don't prescribe, compound, dispense or ship medication, and we have no ownership stake in any company named on this page. We're a consumer research desk covering the metabolic health market.

You should get an answer in writing. The FDA declared the semaglutide shortage resolved in February 2025 and moved in April 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. That removes the legal basis for large-scale compounding. Email your provider today and ask what happens to your prescription and your rate when their compounding source stops. Part 3 covers exactly what to ask.

Read what that label is telling you. "Not for human consumption" is not a technicality and it is not a wink — it means the product was never made to pharmaceutical standards, never prescribed, and never tested for purity, sterility, endotoxin load or correct concentration. If you take one section from the report, take Part 7.

Published GLP-1 trials report average reductions in the range of roughly 15-22% of body weight depending on the medication and dose, over a period of about a year or more. That's a population average, not a prediction — individual results vary widely based on dose, duration, starting point and a dozen clinical factors. Treat any number you see as a rough frame of reference, not a promise.